On Thursday, Dr Soumya Swaminathan , WHO Chief Scientist stated that the data from the phase 3 trial of Bharat Biotech’s vaccine Covexin looks good. Dr Soumya Swaminathan revealed that the pre-submission meeting for Covaxin’s phase 3 trial data was held on June 23 and the data packet is being assembled.
In an interview with a leading news channel , the WHO Chief Scientist said that “The overall efficacy is quite high. The vaccine efficacy against the Delta variant is low but it is still quite good”. The statement comes as Bharat Biotech’s Covaxin awaits WHO approval.
WHO Chief Scientist also said that the organisation still does not not recommend booster shots, adding that it’s important to remain focused on widening the scope of primary Covid-19 vaccinations.
Discussion about this post